UPDATE: Goldman Sachs Maintains Buy, Raises PT to $44 on CVS Caremark

Goldman Sachs reiterates its Buy rating on CVS Caremark

and raises its price target from $43 to $44 per share as the company paints a consistent and upbeat picture. Goldman Sachs notes, "We remain Buy-rated on CVS as its positioning and execution continue to improve, and it offers up a perfect fit for today's large-cap investor wishlist: a predictable operating algorithm and disciplined capital allocation. We raise our 12m PT by $1, to $44, on estimate hikes (on a lower tax rate)." CVS closed at $40.46 per share on Wednesday.